Lidocaine 5% ointment ointment

Šalis: Armėnija

kalba: anglų

Šaltinis: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Veiklioji medžiaga:

lidocaine

Prieinama:

Arpimed LLC

ATC kodas:

N01BB02

INN (Tarptautinis Pavadinimas):

lidocaine

Dozė:

50mg/g

Vaisto forma:

ointment

Vienetai pakuotėje:

aluminium tube 15g

Recepto tipas:

Prescription

Autorizacija statusas:

Registered

Leidimo data:

2020-05-19

Prekės savybės

SUMMARY PRODUCT CHARACTERISTIC (SPC)
LIDOCAINE 5% OINTMENT BRAND NAME – Lidocaine 5% ointment
INTERNATIONAL NON-PROPERTY NAME – Lidocaine PHARMACEUTICAL FORM: Ointment GENERAL CHARACTERISTICS
_ PHYSICAL AND CHEMICAL PROPERTIES _
White homogeneous odorless ointment.
COMPOSITION
Each gram contains:
_ACTIVE INGREDIENT: _ lidocaine – 50 mg; _ INACTIVE INGREDIENTS:_
polyethylene glycol 400, polyethylene
glycol 4000, propylene glycol, water purified.
PHARMACOLOGICAL GROUP AND ATC CODE
Local anaesthetic; N01BB02.
PHARMACOLOGY
Lidocaine is a local anesthetic of the amide type with actions.
Lidocaine blocks the generation and
conduction of impulses through all nerve fibers-sensory, motor, and
autonomic. Lidocaine appears to
block conduction of nerve impulses bу decreasing permeability of the
nerve cell membrane to sodium
ions, thereby decreasing the rate of depolarization of the nerve
membrane, increasing threshold for
electrical excitability, and preventing propagation of the potential. PHARMACOKINETICS
_АBSORPTION:_Lidocaine is readily absorbed from mucous membranes. The
rate and extent of absorption
depends upon concentration and total dose administered, the specific
site of application and duration of
exposure. Perfusion rate in the mucous membranes influences on the
absorption.
_DISTRIBUTION: _Lidocaine is widely distributed into highly perfused
tissues including kidney, lung, liver,
heart, and also penetrates into the adipose tissue. Penetrates into
the placenta by passive diffusion.
Distribution in the placenta may be sufficient to penetrate into the
embryo and achieving toxic levels.
Lidocaine rapidly cross the placenta, appearing in the bloodstream of
the embryo during several
minutes
after
application
by
mother.
Lidocaine
is
bound
to
plasma proteins,
including
α
1
-acid
glycoprotein (AAG). The extent of binding is variable but is about
60-80%. This indicates that the
binding with plasma proteins increases in patients with uraemia and
renal transplant recipients, and
increases after acute myocardial infa